{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T12:49:20Z","timestamp":1770468560153,"version":"3.49.0"},"reference-count":12,"publisher":"BMJ","issue":"12","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2025,11,7]]},"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:p>Levofloxacin, a fluoroquinolone antibiotic, is essential in the treatment protocols for multidrug-resistant tuberculosis (MDR-TB). Generally well tolerated, it infrequently induces central nervous system adverse effects, especially in patients with renal impairment. We present a woman in her early 50s with chronic renal disease and hypothyroidism who experienced focal seizures after 48 hours of commencing levofloxacin as part of her multidrug-resistant tuberculosis treatment regimen. The seizures exhibited unilateral aberrant movements with initially intact consciousness, thereafter followed by brief episodes of altered awareness. Thorough investigations ruled out metabolic, structural and other pharmacological reasons. Seizure activity fully resolved following 3 days of discontinuing levofloxacin, with no recurrence documented during follow-up. This case highlights the importance of recognising levofloxacin-induced neurotoxicity in patients with chronic kidney disease. Dose adjustment, close monitoring and early detection of neurological symptoms are crucial to ensure safe MDR-TB management.<\/jats:p>","DOI":"10.1136\/bcr-2025-269834","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T18:15:39Z","timestamp":1764785739000},"page":"e269834","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Levofloxacin-induced focal seizure in a patient with multidrug-resistant tuberculosis and chronic kidney disease"],"prefix":"10.1136","volume":"18","author":[{"given":"Priyanka","family":"Ramanuj","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Pt. Jawahar Lal Nehru Memorial Medical College, Raipur, Chhattisgarh, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3235-7197","authenticated-orcid":false,"given":"Sameer Uttamrao","family":"Khasbage","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, All India Institute Of Medical Sciences (AIIMS), Raipur, Chhattisgarh, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"key":"2025120310153117000_18.12.e269834.1","unstructured":"World Health Organization . WHO comprehensive guidelines on the management of drug-resistant tb. Geneva World Health Organization; 2019."},{"key":"2025120310153117000_18.12.e269834.2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00113713"},{"key":"2025120310153117000_18.12.e269834.3","doi-asserted-by":"publisher","DOI":"10.1086\/428055"},{"key":"2025120310153117000_18.12.e269834.4","first-page":"465","article-title":"Quinolones: a review of mental and neurological adverse effects","volume":"34","author":"Tom\u00e9","year":"2011","journal-title":"Pharmaceutical Safety"},{"key":"2025120310153117000_18.12.e269834.5","first-page":"171","article-title":"The impact of quinolones and non-steroidal anti-inflammatory agents on GABAA receptors","volume":"243","author":"Halliwell","year":"1993","journal-title":"Eur J Pharmacol"},{"key":"2025120310153117000_18.12.e269834.6","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1128\/AAC.41.10.2256","article-title":"Pharmacokinetic characteristics of levofloxacin after a single daily administration of 500 milligrams via oral or intravenous routes","volume":"41","author":"Chien","year":"1997","journal-title":"Antimicrob Agents Chemother (Bethesda)"},{"key":"2025120310153117000_18.12.e269834.7","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s15010-005-8209-8","article-title":"Immunomodulatory activities of fluoroquinolones","volume":"33 Suppl 2","author":"Dalhoff","year":"2005","journal-title":"Infection"},{"key":"2025120310153117000_18.12.e269834.8","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/45.5.557"},{"key":"2025120310153117000_18.12.e269834.9","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199732020-00002"},{"key":"2025120310153117000_18.12.e269834.10","unstructured":"Prescribing information for levaquin (levofloxacin). Titusville, NJ Janssen Pharmaceuticals; 2019."},{"key":"2025120310153117000_18.12.e269834.11","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1128\/AAC.33.10.1704","article-title":"12] Relationship between the structure of quinolones and their epileptogenicity, with particular emphasis on their interaction with gamma-aminobutyric acid receptor sites","volume":"33","author":"Akahane","year":"1989","journal-title":"Antimicrob Agents Chemother (Bethesda)"},{"key":"2025120310153117000_18.12.e269834.12","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050714"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2025-269834","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T18:15:40Z","timestamp":1764785740000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2025-269834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":12,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12,3]]},"published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1136\/bcr-2025-269834"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2025-269834","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]}}}